These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 1868473)
1. p53 gene mutations in Barrett's epithelium and esophageal cancer. Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA Cancer Res; 1991 Aug; 51(16):4495-9. PubMed ID: 1868473 [TBL] [Abstract][Full Text] [Related]
2. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related]
3. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797 [TBL] [Abstract][Full Text] [Related]
4. p53-mutant clones and field effects in Barrett's esophagus. Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384 [TBL] [Abstract][Full Text] [Related]
5. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry. Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405 [TBL] [Abstract][Full Text] [Related]
6. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus. Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678 [TBL] [Abstract][Full Text] [Related]
7. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858 [TBL] [Abstract][Full Text] [Related]
8. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report. Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596 [TBL] [Abstract][Full Text] [Related]
9. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844 [TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus]. Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305 [TBL] [Abstract][Full Text] [Related]
12. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling. Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019 [TBL] [Abstract][Full Text] [Related]
13. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623 [TBL] [Abstract][Full Text] [Related]
14. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele. Chung SM; Kao J; Hyjek E; Chen YT Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662 [TBL] [Abstract][Full Text] [Related]
15. p53 mutational spectrum of esophageal carcinomas from five different geographical locales in China. Lung ML; Chan WC; Zong YS; Tang CM; Fok CL; Wong KT; Chan LK; Lau KW Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):277-84. PubMed ID: 8722219 [TBL] [Abstract][Full Text] [Related]
16. Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett's esophagus. Miyazono F; Schneider PM; Metzger R; Warnecke-Eberz U; Baldus SE; Dienes HP; Aikou T; Hoelscher AH Oncogene; 2002 May; 21(23):3780-3. PubMed ID: 12032845 [TBL] [Abstract][Full Text] [Related]
17. [Profile of p53 mutations and abnormal expression of P53 protein in 2 forms of esophageal cancer]. Muzeau F; Fléjou JF; Potet F; Belghiti J; Thomas G; Hamelin R Gastroenterol Clin Biol; 1996; 20(5):430-7. PubMed ID: 8761140 [TBL] [Abstract][Full Text] [Related]
18. p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study. Sorsdahl K; Casson AG; Troster M; Van Meyel D; Inculet R; Chambers AF Cancer Detect Prev; 1994; 18(3):179-85. PubMed ID: 8076380 [TBL] [Abstract][Full Text] [Related]
19. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218 [TBL] [Abstract][Full Text] [Related]